Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Robert T. Brodell MD, FAAD Editor-in-Chief

Ashish C. Bhatia MD, FAAD Associate Editor

Christen Maria Mowad MD Advisory Board

See All Experts

featured

Published in Dermatology

Journal Scan / Research · November 19, 2024

Outcomes of Continued Ritlecitinib Treatment Through Week 48 in Patients With Alopecia Areata With or Without Early Target Responses

Journal of the American Academy of Dermatology

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Outcomes of Down-Titration in Patients With Severe Scalp Alopecia Areata Initially Treated With Baricitinib 4 mg

Journal of the American Academy of Dermatology

Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial

J Am Acad Dermatol 2024 Oct 17;[EPub Ahead of Print], M Piliang, C Lynde, B King, P Mirmirani, R Sinclair, M Senna, S Forman, L Bordone, P De La Cueva Dobao, R Wolk, SH Zwillich, H Tran, D Wajsbrot, HM Ahmed, L Takiya

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Outcomes of Continued Ritlecitinib Treatment Through Week 48 in Patients With Alopecia Areata With or Without Early Target Responses

Additional Info

Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial

Further Reading

Efficacy and Safety of Tofacitinib vs Azathioprine in Patients With Alopecia Areata and Its Variants

Outcomes of Down-Titration in Patients With Severe Scalp Alopecia Areata Initially Treated With Baricitinib 4 mg

Association Between 5α-Reductase Inhibitor Use for Dermatologic Conditions and the Risk of Breast or Gynecologic Cancers

Safety and Effectiveness of a Targeted Alkali Thermolysis Patch for the Treatment of Patients With Primary Axillary Hyperhidrosis or Excessive Axillary Sweating

Outcomes of Continued Ritlecitinib Treatment Through Week 48 in Patients With Alopecia Areata With or Without Early Target Responses

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis

Association Between Treatment With Biologics and Cardiovascular Comorbidities in Patients With Psoriasis

Evaluation and Surgical Management of Pediatric Cutaneous Melanoma, Atypical Spitz Tumors, and Non-Spitz Melanocytic Tumors

Safety of Biologic Use During Pregnancy and Breastfeeding in Dermatology

Impact of Clinical Information on Melanocytic Skin Lesion Pathology Diagnosis

Local Recurrence, Metastasis, and Mortality Rates Among Patients With Thin and In Situ Melanomas

Recently Updated